Results 191 to 200 of about 128,993 (222)
Some of the next articles are maybe not open access.
2022
More specifically, this thesis examines the information exchange between originator manufacturers and biosimilar manufacturers related to patents and data exclusivity, and how the information exchange affects biosimilars and biosimilar development.
openaire +1 more source
More specifically, this thesis examines the information exchange between originator manufacturers and biosimilar manufacturers related to patents and data exclusivity, and how the information exchange affects biosimilars and biosimilar development.
openaire +1 more source
International Journal of Advanced Multidisciplinary Research and Studies
Biosimilars were introduced into regulated markets as a cost containment mechanism modelled loosely on small molecule generics. This paper argues that their more consequential effect has been structural rather than fiscal: Biosimilars have dismantled the marketing logic on which the branded biologics industry was built.
Imoiboho Williams +2 more
openaire +1 more source
Biosimilars were introduced into regulated markets as a cost containment mechanism modelled loosely on small molecule generics. This paper argues that their more consequential effect has been structural rather than fiscal: Biosimilars have dismantled the marketing logic on which the branded biologics industry was built.
Imoiboho Williams +2 more
openaire +1 more source
Naunyn-Schmiedeberg's Archives of Pharmacology
Information on biosimilars was rarely disseminated on the Pharmaceuticals and Medical Devices Agency (PMDA) website of the Japanese Regulatory Agency until the fiscal year (FY) 2022. Therefore, the PMDA website for biosimilars was created in FY 2023.
Ryosuke Kuribayashi +3 more
openaire +2 more sources
Information on biosimilars was rarely disseminated on the Pharmaceuticals and Medical Devices Agency (PMDA) website of the Japanese Regulatory Agency until the fiscal year (FY) 2022. Therefore, the PMDA website for biosimilars was created in FY 2023.
Ryosuke Kuribayashi +3 more
openaire +2 more sources
Journal of European Economic History
The global pharmaceutical industry has undergone a paradigm shift from the dominance of blockbuster small-molecule drugs to biologics and biosimilars. This transformation is driven by patent expirations, escalating research and development (R&D) costs, advancements in biotechnology, and the increasing burden of chronic diseases.
openaire +1 more source
The global pharmaceutical industry has undergone a paradigm shift from the dominance of blockbuster small-molecule drugs to biologics and biosimilars. This transformation is driven by patent expirations, escalating research and development (R&D) costs, advancements in biotechnology, and the increasing burden of chronic diseases.
openaire +1 more source
Biosimilars Pharmaceutical Market in India: Current Status, Challenges and Future Perspective
Bioscience Biotechnology Research Communications, 2021openaire +1 more source
Transforming Drug Design: Innovations in Computer-Aided Discovery for Biosimilar Agents
BioMedInformatics, 2023Hamed Taherdoost
exaly

